Shares of Celsion Co. (NASDAQ:CLSN) have earned an average recommendation of “Buy” from the six analysts that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $14.50.
CLSN has been the subject of several recent analyst reports. Maxim Group upgraded Celsion from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a research note on Wednesday, October 4th. ValuEngine upgraded Celsion from a “strong sell” rating to a “sell” rating in a research note on Saturday, December 9th. Zacks Investment Research upgraded Celsion from a “sell” rating to a “hold” rating in a research note on Tuesday, December 19th. Finally, Oppenheimer initiated coverage on Celsion in a research note on Tuesday, November 21st. They set an “outperform” rating and a $9.00 target price for the company.
Shares of Celsion (NASDAQ:CLSN) opened at $2.75 on Wednesday. The firm has a market capitalization of $44.17, a P/E ratio of -0.47 and a beta of 1.22. Celsion has a 52 week low of $1.24 and a 52 week high of $8.82.
WARNING: This article was first reported by BBNS and is the property of of BBNS. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://baseballnewssource.com/markets/celsion-co-clsn-given-consensus-recommendation-of-buy-by-brokerages/1822390.html.
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.